PROGRESSIVE CORP. DL 1/ US7433151039 /
7/26/2024 9:58:16 AM | Chg. -1.3200 | Volume | Bid9:59:32 PM | Ask9:59:32 PM | Market Capitalization | Dividend Y. | P/E Ratio |
---|---|---|---|---|---|---|---|
197.6600EUR | -0.66% | 6 Turnover: 1,185.9600 |
-Bid Size: - | -Ask Size: - | 116.34 bill.EUR | - | - |
GlobeNewswire
6/25
argenx Highlights Breadth of Autoimmune Pipeline with New Multifocal Motor Neuropathy Data at 2024 P...
GlobeNewswire
6/24
Enlivex Announces the Dosing of the First Patient in a Randomized, Placebo-Controlled Phase I/II Tri...
GlobeNewswire
6/24
4DMT Announces FDA Clearance of IND Application for 4D-175 Genetic Medicine for the Treatment of Geo...
GlobeNewswire
6/24
Entrada Therapeutics Reports Positive Preliminary Data in Healthy Volunteers from Phase 1 ENTR-601-4...
GlobeNewswire
6/13
Dyne Therapeutics Presents New Preclinical Data for its Facioscapulohumeral Muscular Dystrophy Progr...
GlobeNewswire
6/12
Ultragenyx Announces Plans to File for Accelerated Approval of UX111 for the Treatment of Sanfilippo...
GlobeNewswire
6/12
Belite Bio Receives Sakigake (Pioneer Drug) Designation of Tinlarebant for Stargardt Disease in Japa...
GlobeNewswire
6/11
Global Multiple Sclerosis Drugs Market Size Projected to Reach $38 Billion By 2032 as Demand on R&D ...
GlobeNewswire
6/11
Processa Pharmaceuticals Announces Positive Efficacy Results from Preliminary Evaluation of Phase 1b...
GlobeNewswire
6/11
FDA Accepts Tiziana Life Sciences Fast Track Designation Submission for Treatment of Multiple Sclero...
GlobeNewswire
6/10
LifeWallet’s Proprietary Data System is Instrumental in Class Certification Against USAA Property an...